Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 79

of 'Management of acute chemotherapy-related diarrhea'

Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.
VAN DEN Heuvel B, Peeters M, Hendlisz A, VAN DEN Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, VAN Laethem JL, Lybaert W, Holbrechts S, Rolfo C
Minerva Chir. 2016 Jan;
BACKGROUND: The aim of this study is to investigate the role of Octreotide LAR in secondary prevention in patients with chemotherapy-induced diarrhea.
METHODS: In this study, patients experiencing CID≥grade 2 received 30 mg long-acting octreotide as a monthly injection and the next chemotherapy dose was administrated with a 25% dose decrease. If no CID≥grade 2 occurred, subsequent chemotherapy doses were increased to the initial 100% values. The primary endpoint of the study was the diarrhea control rate (<grade 2) for patients receiving the optimal dose of chemotherapy for a minimum of 2 cycles.
RESULTS: Twenty-nine patients were included. Ten patients experienced no improvement or ended the study very early after the first injection of octreotide LAR. Nineteen patients had a reduction in the grade of diarrhea after the first administration of Octreotide LAR and a reduced chemotherapy dose. Seven of them (24%) did not reach the end of the study because of disease progression (6) or lost in follow-up (1). Ultimately 12 patients (41%) continued the study till the end. In ten of these twelve patients, there was a significant and persisting reduction of diarrhea while receiving full dose chemotherapy.
CONCLUSION: This study suggests that monthly injections with long-acting octreotide might be used as a secondary prevention of chemotherapy-induced diarrhea. Its usefulness and optimal dosage in secondary prevention in combination with antidiarrheal agents needs further research.
Department of medical oncology, Antwerp University Hospital, Antwerp, University of Antwerp, Antwerp, Belgium - bert.vandenheuvel@uza.be.